Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO ...

Pfizer ( PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

Pfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US ...

Pfizer CEO Albert Bourla cashed in on his company’s coronavirus vaccine breakthrough. The executive sold more than $5.5 million worth of Pfizer stock on Monday — the same day the drugmaker sa… ...

"Pfizer CEO Albert Burla (sic) is stepping down and now says the mRNA technology was not sufficiently proven when launched," reads the caption of a Dec. 10 Facebook clip (direct link, archived link).

Pfizer CEO Albert Bourla said Monday he hasn’t taken the COVID-19 vaccine yet — but only because he doesn’t want to be seen as jumping the line.

Pfizer CEO Albert Bourla on Tuesday said the company believes a COVID-19 vaccine-resistant variant will likely one day emerge, though the company has a system in place to turn around a variant ...

Pfizer CEO Albert Bourla delivers a speech during the inauguration ceremony of the company's new center for Digital Innovation and Business Operations and Services in Thessaloniki, Greece.